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Abstract
The lysosomal storage disorder Fabry disease (FD) is caused by pathogenic mutations in the a-galactosidase A gene, localized in X
chromosome. Deficient enzymatic activity of the product of this gene, the lysosomal hydrolase a-galactosidase A, leads to
accumulation of its substrate globotriaosylceramide. Diagnosis of FD starts with clinical suspicion followed by confirmatory
laboratory testing. The aim of this work is to report the 14 years’ experience and learnings in the diagnosis of patients with
Fabry disease in Argentina from a specialized lysosomal diseases diagnosis laboratory and to report the genotype
characterization of the 25 families from Argentina with FD detected by us.
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Introduction
The lysosomal storage disorder Fabry disease (FD) is caused by
pathogenic mutations in the a-galactosidase A (GLA) gene,
localized in X chromosome. Deficient enzymatic activity of the
product of this gene, the lysosomal hydrolase a-galactosidase
A (aGalA), leads to accumulation of its substrates globotriao-
sylceramide (Gb3) and lyso-Gb3.1 Low or absent enzyme
activity in men provokes signs and symptoms of classical
FD, which is characterized by acroparesthesia, angiokeratoma,
hypohydrosis, renal dysfunction, and cornea verticillata. Com-
plications of heart, kidney, and brain are the main cause of
death, reducing life expectancy for 20 years when compared
to normal population. Heterozygous females are usually also
affected, displaying a broader spectrum of phenotypes, from
moderate to severe disease.2 There are also patients with
Fabry disease with a different phenotype, called ‘‘late-onset
variants,’’ characterized by a lack in typical manifestations
such as acroparesthesia, angiokeratoma, or cornea verticillata
but displaying its main problems in kidney, heart, and/or cen-
tral nervous system appearing at a later age.3 Prevalence of
FD was previously estimated to be between 1:40 000 and
170 000,4,5 however pilot newborn screening studies showed
higher prevalence of 1 of 3600.6
Prior to laboratory studies, diagnosis of FD starts with thor-
ough clinical examination of the patient, his medical, and fam-
ily history. Based on all these data, if the physician established
there is clinical suspicion for FD, laboratory testing is the next
step. Laboratory diagnosis of FD in males, as recommended by
a consensus of a European expert group, is carried out by deter-
mination of aGalA activity. It can be measured in samples such
as dried blood spots, plasma, leukocytes, or fibroblasts, how-
ever the ‘‘gold standard’’ for definite diagnosis is leukocytes
or fibroblasts. The following test should be mutation analysis,
which is useful to confirm diagnosis, discard possible pseudo-
deficiency cases (eg, D313Y),7 and to mainly diagnose female
relatives at risk of being heterozygote, and genetic counseling.
On the other hand, for females, enzymatic activity determination
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is inconclusive, and only the identification of a pathogenic muta-
tion in GLA gene allows definite diagnosis.8
The aim of this work is to report the 14 years’ experience in
diagnosis of patients with Fabry disease in Argentina from a
specialized lysosomal diseases diagnosis laboratory. Moreover,
we report genotype characterization of the 25 families from
Argentina with FD detected by us.
Materials and Methods
Targeted Screening Strategy
Physicians who suspected FD in their patients through clinical
manifestations sent blood samples to the laboratory for bio-
chemical and genetic assays. The number of samples received
by clinical suspicion was 589. After a new Fabry patient was
detected, the screening of the whole family was performed.
We have collected 1274 samples from relatives of the different
Fabry index cases.
High-Risk Screenings Strategy
Dried blood samples (n ¼ 1401) from males at hemodialysis
centers were collected and used for enzyme assay.
Patient Samples
The study period is from January 2002 to June 2015. Blood
samples were collected by venipuncture. We received dried
blood spots from male patients for enzymatic activity assay.
If the result was pathologic, 9 mL of heparin blood and 1 mL
of EDTA blood were asked thereafter in order to confirm the
diagnosis by measuring a-GalA activity in leukocytes and
genetic test. EDTA blood was received from female patients
for genetic test.
Enzymatic Activity Determination
The aGalA activity determination was carried out on dried
blood filter paper, according to the method of Chamoles
et al9 and described in Ceci et al.10
Mutation Detection in GLA Gene
Mutation analysis was done using DNA isolated from EDTA
blood samples. Polymerase chain reaction amplification of
each exon and adjacent intron–exon boundaries by the use of
specific primers was carried out. The amplicons were purified
and then sequenced in both directions in a DNA Sequencing
device (Applied Biosystems, Foster City, California).
Results and Discussion
Fabry Index Cases and Mutations
In the period of this work, 25 Fabry new index patients were
detected and diagnosed. Most of the index cases were males
(n ¼ 22), and 3 were females. We have found the mutation
in all the 25 families with FD detected by us in Argentina
(Table 1). Each family had a different mutation, so the rate
of private mutations was 100%. Most of the alleles were mis-
sense mutations, accounting for 72% of them, and moreover
we found 3 short deletions, 2 short duplications, and 2 nonsense
mutations (Figure 1). We have not found any complete exon/
gene deletion, splicing, or gross rearrangements. All the dupli-
cations and deletions were novel, but only 5 missense and one
nonsense mutations were novel.
Average age at diagnosis was 39 years old, and the range was
between 15 and 72 years old. Data captured in Fabry registries
included worldwide data, such as Fabry outcome survey (FOS),
and reported a lower age.23 However, the age at diagnosis is
higher than the age at onset of symptoms, and there is a delay
of diagnosis of at least 10 years. The delayed age at diagnosis
found in Argentina is completely in agreement with what is
happening in other parts of the world, meaning it does not
depend on the development or economic status of the country.
In spite of multiple efforts invested in dissemination of knowl-
edge among medical community, delay between symptoms
onset and age at diagnosis has no changed in the last years.
Absence of the probands’ mutations in their mother suggests
that in 5 cases, the mutations occurred de novo (20%). How-
ever, the possibility of germinal mosaicism could not be ruled
out. This percentage is higher than the theoretical value of 3%
to 10% based on the reproductive fitness of 0.7 to 0.9,24 a birth
frequency of 1:40.000 to 1:100.000, and a GLA mutation rate
of 1  10-6.25
Classical Cases
It is well established that FD is still an underdiagnosed disorder
worldwide.27 Regarding both phenotypes of FD, classical cases
are easier to suspect than variant ones. The clinical picture in
classical cases, meaning the full clinical manifestations and
family history altogether, is highly suggestive, and if it is
observed by an expert physician in FD, the clinical suspicion
is usually made. In our cohort, 17 of the classical cases were
detected by clinical suspicion of physicians from different spe-
cialties, including nephrologists (59%), dermatologists (17%),
cardiologists (6%), neurologists (12%), and clinicians (6%)
(Figure 2). Three of the cases are included in the table as
detected by the patient itself. One of them was diagnosed
because a relative of the patient living in another country was
diagnosed, so he contacted a referent specialist in FD. The sec-
ond one was suspected when the patient went to a commercial
shop owned by a previously diagnosed Fabry patient, and he
complained about having suffered a renal transplant 3 months
ago and with clinical symptoms such as heat intolerance, hypo-
hydrosis, and acroparesthesia. The Fabry patient recognized the
symptoms, asked about the presence of angiokeratoma that was
confirmed, and derived the patient to a specialist, and the dis-
ease was lately confirmed. The last case was detected when his
grandmother wrote in a rare disease patient forum, describing
the symptoms of his grandchild; a Fabry patient in the forum
2 Journal of Inborn Errors of Metabolism & Screening
T
a
b
le
1
.
Li
st
o
f
M
u
ta
ti
o
n
s
Fr
o
m
2
5
Fa
m
ili
es
o
f
A
rg
en
ti
n
ea
n
p
at
ie
n
ts
w
it
h
Fa
b
ry
d
is
ea
se
.a
Fa
m
ily
cD
N
A
E
x
o
n
P
ro
te
in
T
yp
e
o
f
M
u
ta
ti
o
n
R
ef
er
en
ce
D
e
n
o
vo
Sp
ec
ia
lis
t
P
h
en
o
ty
p
e
A
ge
at
D
ia
gn
o
si
s
R
el
at
iv
es
St
u
d
ie
d
N
u
m
b
er
o
f
P
o
si
-
ti
ve
R
el
at
iv
es
1
c.
6
7
9
C
>
T
5
p
.A
rg
2
2
7
X
N
o
n
se
n
se
1
1
N
ep
h
ro
lo
gi
st
C
la
ss
ic
2
4
2
5
3
8
2
c.
7
2
8
T
>
G
5
p
.L
eu
2
4
3
T
rp
M
is
se
n
se
1
2
N
ep
h
ro
lo
gi
st
C
la
ss
ic
3
9
5
4
5
3
c.
4
6
3
G
>
C
3
p
.A
sp
1
5
5
H
is
M
is
se
n
se
1
3
D
er
m
at
o
lo
gi
st
C
la
ss
ic
2
3
3
1
9
7
3
4
c.
1
2
4
4
T
>
C
7
p
.L
eu
4
1
5
P
ro
M
is
se
n
se
1
4
D
er
m
at
o
lo
gi
st
C
la
ss
ic
3
2
6
7
1
8
5
c.
2
8
1
G
>
A
2
p
.C
ys
9
4
T
yr
M
is
se
n
se
3
N
ep
h
ro
lo
gi
st
C
la
ss
ic
4
6
1
3
8
6
c.
5
7
2
T
>
C
4
p
.L
eu
1
9
1
P
ro
M
is
se
n
se
C
o
o
p
er
,
1
9
9
8
P
at
ie
n
t
C
la
ss
ic
2
5
5
2
7
c.
1
0
8
8
G
>
A
7
p
.A
rg
3
6
3
H
is
M
is
se
n
se
C
o
o
p
er
,
1
9
9
8
Sc
re
en
in
g
h
em
o
d
ia
ly
si
s
V
ar
ia
n
t
(C
er
eb
ro
va
sc
u
la
r)
6
2
9
5
8
c.
2
8
6
-2
8
7
d
u
p
A
2
T
ru
n
ca
te
d
Fr
am
es
h
ift
N
ep
h
ro
lo
gi
st
C
la
ss
ic
4
6
3
2
9
c.
5
8
1
C
>
T
4
p
.T
h
r1
9
4
Ile
M
is
se
n
se
1
5
P
at
ie
n
t
C
la
ss
ic
4
4
5
9
2
9
1
0
c.
8
7
4
G
>
A
6
p
.A
la
2
9
2
T
h
r
M
is
se
n
se
1
6
C
lin
ic
ia
n
C
la
ss
ic
2
7
8
8
1
1
c.
1
1
4
5
G
>
A
7
p
.C
ys
3
8
2
T
yr
M
is
se
n
se
1
7
D
e
n
o
vo
N
ep
h
ro
lo
gi
st
C
la
ss
ic
3
0
3
1
1
2
c.
5
2
0
T
>
G
3
p
.C
ys
1
7
4
G
ly
M
is
se
n
se
C
ar
d
io
lo
gi
st
V
ar
ia
n
t
(C
ar
d
ia
c)
5
6
2
7
9
5
1
1
3
c.
6
8
0
G
>
A
5
p
.A
rg
2
2
7
G
ln
M
is
se
n
se
1
8
D
er
m
at
o
lo
gi
st
C
la
ss
ic
2
6
1
5
8
1
4
c.
7
9
0
G
>
T
5
p
.A
sp
2
6
4
T
yr
M
is
se
n
se
1
9
N
eu
ro
lo
gi
st
C
la
ss
ic
6
2
3
2
1
5
c.
1
1
2
2
_
1
1
2
5
d
el
A
G
G
A
7
T
ru
n
ca
te
d
Fr
am
es
h
ift
N
ep
h
ro
lo
gi
st
C
la
ss
ic
3
1
5
2
1
6
c.
1
6
0
C
>
U
1
p
.L
eu
5
4
P
h
e
M
is
se
n
se
N
ep
h
ro
lo
gi
st
V
ar
ia
n
t
(r
en
al
)
5
0
6
3
1
7
c.
6
4
4
A
>
G
5
p
.A
sn
2
1
5
Se
r
M
is
se
n
se
1
1
N
ep
hr
o
lo
gi
st
/p
at
ho
lo
gi
st
V
ar
ia
n
t
(r
en
al
)
6
1
7
5
1
5
1
8
c.
6
4
7
A
>
G
5
p
.T
yr
2
1
6
C
ys
M
is
se
n
se
2
0
N
eu
ro
lo
gi
st
C
la
ss
ic
2
6
1
1
6
1
9
c.
4
4
8
d
el
G
3
T
ru
n
ca
te
d
Fr
am
es
h
ift
D
e
n
o
vo
N
ep
h
ro
lo
gi
st
C
la
ss
ic
3
0
4
1
2
0
c.
7
7
2
G
>
T
5
p
.G
ly
2
5
8
St
o
p
N
o
n
se
n
se
D
e
n
o
vo
N
ep
h
ro
lo
gi
st
C
la
ss
ic
4
5
1
3
2
2
1
c.
7
8
2
-7
8
3
d
u
p
G
5
T
ru
n
ca
te
d
Fr
am
es
h
ift
D
e
n
o
vo
N
ep
h
ro
lo
gi
st
C
la
ss
ic
4
6
5
1
2
2
c.
7
1
8
_
7
1
9
d
el
A
A
5
T
ru
n
ca
te
d
Fr
am
es
h
ift
D
e
n
o
vo
P
at
ie
n
t
C
la
ss
ic
1
5
3
1
2
3
c.
3
3
5
G
>
A
2
p
.A
rg
1
1
2
H
is
M
is
se
n
se
2
1
Sc
re
en
in
g
h
em
o
d
ia
ly
si
s
V
ar
ia
n
t
(r
en
al
)
7
2
2
4
1
5
2
4
c.
9
0
2
G
>
A
6
p
.A
rg
3
0
1
G
ln
M
is
se
n
se
2
2
C
ar
d
io
lo
gi
st
C
la
ss
ic
4
8
3
5
1
7
2
5
c.
1
0
0
A
>
G
1
p
.A
sn
3
4
A
sp
M
is
se
n
se
N
ep
h
ro
lo
gi
st
C
la
ss
ic
1
6
3
3
A
b
b
re
vi
at
io
n
:
cD
N
A
,
co
m
p
le
m
en
ta
ry
D
N
A
.
a A
ls
o
sh
o
w
n
is
th
e
p
h
en
o
ty
p
e
o
ft
h
e
in
d
ex
p
at
ie
n
t,
th
e
sp
ec
ia
lis
t
w
h
o
m
ad
e
th
e
cl
in
ic
al
su
sp
ic
io
n
,t
h
e
re
fe
re
n
ce
if
th
e
m
u
ta
ti
o
n
h
as
b
ee
n
re
p
o
rt
ed
,t
h
e
ag
e
at
d
ia
gn
o
si
s
o
ft
h
e
in
d
ex
ca
se
,a
n
d
th
e
n
u
m
b
er
o
fm
em
b
er
s
o
fe
ac
h
fa
m
ily
th
at
w
er
e
st
u
d
ie
d
an
d
th
e
n
u
m
b
er
o
f
p
o
si
ti
ve
o
n
es
.
3
realized he could have FD and made the contact with the phy-
sician to initiate diagnosis process confirming the disease.
Average age at diagnosis among classical cases is 34 years old,
and the range is between 15 and 62 years old.
Variant Cases
Variant cases are the most difficult to suspect and identify.
Among the phenotypes found in the cohort of 25 Fabry fami-
lies, 5 were variant cases. Two of them were the ones detected
by high-risk screenings. The cardiac variant case was detected
by a cardiologist specialized in echocardiography and sus-
pected FD through echo image after he attended a conference
about FD. One of the renal variants detected by a nephrologist
was suspected after kidney biopsy. The biopsy revealed foamy
cells in the glomerulus, and the pathologist suggested FD as
probable diagnosis. Average age at diagnosis among variant
cases is 60 years old, and the range is between 56 and 72 years
old. This higher age is not surprising taking into account the
lack of manifestations at younger age.
Paternity Issues
X-linked inheritance of FD in which male reproductive fitness
is normal could expose out paternity issues. Genetic counselors
have to be extremely cautious in this aspect when talking with
relatives of patients with Fabry disease during family screen-
ing. Daughter of a Fabry male should be obligate heterozygote.
We avoid using the word obligate inheritance when talking
about daughters who do not have Fabry sons, yet. We always
explain the families the genetic test is mandatory, and it is the
solely way of confirmation of Fabry diagnosis. In our cohort,
we had the experience of 2 families with paternity issues. We
tested daughters from Fabry males but the genetic test was
negative.
Oocyte Donation
One interesting anecdote showed up during screening for FD in
a family after detection of a new patient. Two female relatives
of the index Fabry patient were donating eggs for purposes
of assisted reproduction as third-party reproduction. To our
knowledge, 30 births arose from eggs of these Fabry women
during 7 years. One of the families came to us for diagnosis
of their male baby, and unfortunately it was positive. As con-
clusion of this case, physicians should ask every new patient
if he or she is donating sperm/eggs in the anamnesis.
Detection of Patients by Clinical Suspicion
Since we opened the service of lysosomal disorders, we have
assayed 3264 samples for Fabry diagnosis. From the total num-
ber of samples assayed, 589 samples (18% from total samples
assayed for Fabry diagnosis) were sent by physicians after clin-
ical suspicion of FD during the first visit of the patient to his
consultation. Among them, diagnosis of FD was confirmed in
23 patients, a percentage of 4%. In a simplistic point of view,
it could be thought that the yield of 4% could be low. However,
taking into account it is a rare disease, the constellation of
unspecific signs and symptoms, the low awareness among
medical community, this point of view changes to a more pos-
itive one. Most of the index cases were males, but 3 of them
were females. There are a lot of advantages of this result.
Twenty-three persons finally obtained their confirmed diagno-
sis, after being consulting from more than 10 years with more
than 10 medical specialists in a process called ‘‘odyssey diag-
nostic.’’ Confirmatory diagnosis finishes this unpleasant pro-
cess for the patient and his family. Moreover, each patient
could now benefit from instauration of a specific treatment now
available since 2003.
Detection of Patients by Family Screening
One of the greatest benefits of detection of undiagnosed
patients with Fabry disease is for his or her family. FD is a
genetic condition, and the mutation is transmitted from parents
to children, so generally once a new patient is detected, the
whole family could be screened and more previously undiag-
nosed patients are confirmed with FD. Diagnosis of relatives
arrives earlier as compared as if the patients would have been
diagnosed by clinical suspicion. Moreover, some patients are
Figure 1. Type of mutations detected in patients with Fabry disease
from Argentina (%).
Figure 2. Specialists who made clinical suspicion (%).
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diagnosed at an earlier age, before irreversible complications in
organs, and are the most benefitted with this family screening
process. Family screening starts with pedigree analysis. Geneti-
cists should build the genealogic tree together with the family
and give genetic counseling to the family. Genetic counseling
includes, among others, telling the risk of affected couples to
have affected children at each pregnancy and underscore which
relatives could be at risk of being patients and therefore who
should be tested.
Working with all the index cases detected and building each
family tree, we offered the relatives at risk the possibility of
being tested in order to obtain confirmatory diagnosis. And our
experience is the following. We have taken 1274 samples from
relatives, corresponding to 39% of the samples analyzed in our
laboratory for Fabry diagnosis. And the proportion of positive
diagnosis is 22%, representing 286 new patients with Fabry dis-
ease with definitive diagnosis, who benefit from avoiding suf-
fering the odyssey and from an early instauration of treatment if
necessary as decided by medical judgment. It is obvious to say,
family screening in FD is the higher performance way to detect
patients with Fabry disease and for many of the cases diagnosis
is obtained at a lower age as compared to the average.
Detection of Patients by High-Risk Screenings
As we said earlier, detection of patients with Fabry disease is a
hard and difficult task. There are many patients still undiag-
nosed in the world. Together with the advent of specific ther-
apy whose benefit may be better when initiating early have
prompted researchers to perform screening studies for FD in
high risk populations. The meaning of high risk includes
patients who express at least one sign or symptom that could
be caused by FD. Several studies of this type have been carried
out, and the high risk populations included patients on or with
hemodialysis, renal transplant, left ventricular hypertrophy,
and stroke, as the main ones, and others were patients with
small fiber peripheral neuropathy, angiokeratoma, or cornea
verticillata.
One of the main issues is the type of laboratory assays that
should be carried out in screenings.28 Determination of enzy-
matic activity is used when analyzing male samples, mainly
in dried blood spots. When a pathogenic result is obtained, it
should be confirmed in leukocytes. The final diagnosis is
accompanied by genetic test establishing the presence of a
pathogenic mutation. When females are included, genetic test
is mandatory. In many cases, the pathogenicity of the mutation
can’t be established, they are called genetic variants with
unknown significance (GVUS).29 In cases with GVUS, there
is an uncertain diagnosis of FD, and enzyme replacement ther-
apy should not be started. Van der Tol et al suggest using an
electron microscopy analysis of the biopsy of the affected
organ to look for Gb3 deposits. Gb3 and Lyso-Gb3 in urine
and/or plasma could also be measured, however the usefulness
is limited in variant cases or females.30 Another useful strategy
it is to undergo a thorough family testing, especially to find
males with low aGalA activity and the same mutation that
would support the mutation being pathogenic.31 And if the
diagnosis cannot be confirmed, the patient remains in study
until a confirmatory result, positive or negative, could be given.
In Argentina, we have carried out screenings in hemodialy-
sis patients. We have assayed 1401 samples representing 43%
of the samples assayed for FD. By this studies, we confirmed
Fabry diagnosis in 2 patients, giving a yield of 0.1%. This type
of looking for patients with Fabry disease is the one with poor
performance. But again, the positive view is that 2 new families
with various relatives have benefit from correct diagnosis.
Clinical Suspicion Versus High-Risk Screenings: Analysis
of Yield and Cost–Benefit
The cost–benefit analysis is difficult to undergone when talking
about medicine, disease, and patients. Ethical issues may arise
when this discussion is taking place. And it is our opinion that
all suffering patients deserve to obtain the better up to date
attention from biomedical specialists. No patient should be left
apart from the best care of the moment.
If we only put attention on numbers and proportion of posi-
tives, there is no doubt that detection of patients with Fabry dis-
ease by medical suspicion is the best option. The classical way to
detect patients in clinical visit is still the best. For this reason,
awareness in medical community about FD should be one of the
main activities from reference professionals in the field of lyso-
somal diseases. Different specialists could suspect FD in their
patients, such as nephrologists, cardiologists, rheumatologists,
dermatologists,23 and also searching with Google may lead to
a diagnosis.32 On the other side, in our experience, both patients
detected by high risk screening were variant cases, the most dif-
ficult to find among the phenotypes of FD. And, surely we
wouldn’t find those cases without this screening. The main dis-
advantages of screening in populations with one of the symp-
toms of Fabry’s are to find cases in which the final diagnosis
can’t be established. Moreover, the worst thing is when this pro-
cess is undergone and analyzed by nonreference professionals
that may make a mistake in the interpretation of the results.
There are examples in literature considering diagnosis of FD
in patients whose pathogenicity of the mutation could be wrong
or couldn’t be finally established.33 The mutation D313Y causes
a reduced enzymatic activity of aGalA toward the artificial sub-
strate in the in vitro test, however expression studies demon-
strated high residual activity and no significant accumulation
of the substrate Gb3. Now, mutation D313Y is considered a
polymorphism, it is present in 1% of control population, and
causes a ‘‘seudodeficiency.’’34
Over Suspicion
A new emergence challenge in the field of Fabry diagnosis is
over suspicion. The benefit of continuing medical education
in terms of better awareness that is so important in rare diseases
could have the potential impact of being over suspected. More-
over, the idea of having a specific therapy to offer to a potential
patient made the physician to put FD as one of the first in the
Rozenfeld et al 5
list of diseases for differential diagnosis when only one sign of
symptom is present in his or her patient. This aspect was
detected by us as a reference lab with personal specialized in
Fabry diagnosis. In the last couple of years, we are receiving
more samples from too many different physicians, and the pro-
portion of positive cases that was 8% in our first years of work
has declined to the 4% we reported above. Having detected this
over suspicion, we are more cautious and ask the physicians to
send a more complete clinical picture, medical history, and
family history in order to decide, especially in females, which
samples should be tested.
Conclusion
In this work, we presented our 14 years’ experience in diagno-
sis of Fabry disease in Argentina from a specialized lysosomal
diseases diagnosis laboratory. Moreover, we report genotype
characterization of the 25 families from Argentina with FD
detected by us. Although there are reports of mutations in
patients with Fabry disease from Argentina, it is the biggest
report of mutations of FD in Argentina. The mutations were
missense in 72% of the cases, 3 short deletions, 2 short dupli-
cations, and 2 nonsense mutations. All the duplications and
deletions were novel, but only 5 missense and 1 nonsense muta-
tions were novel. We have no found exon or gene deletions.
This challenge was approached by medical education, close
contact with the physicians who suspect FD in their patients,
and working with affected families in order to offer diagnosis.
All this work is carried out in close collaboration with a group
of physicians of different specialties, who are gathered in
AADELFA, a medical association for study of Fabry disease
in Argentina.
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